Company N ame: Swiss Re AG
Company Ticker: SREN SW Equity
Date: 2021-07-30

S1 2021 Earnings Call
Company Participants
FINAL

Christian Mumenthaler, Group Chief Executive Officer
John Dacey, Group Chief Financial Officer
Thierry Leger, Group Chief Underwriting Officer
Thomas Bohun, Head of Investor Relations

Other Participants
Andrew Ritchie , Analyst
Ashik Musaddi, Analyst
Iain Pearce , Analyst
Ivan Bokhmat, Analyst
James Shuck, Analyst
Kamran Hossain, Analyst
Thomas Fossard, Analyst
Vikram Gandhi, Analyst
Vinit Malhotra, Analyst

Bloomberg Transcript

Will Hardcastle , Analyst

Presentation
Operator
(Start Abruptly) turn the conference over to Mr. Christian Mumenthaler, Group CEO. Please
go ahead.

Christian Mumenthaler

{BIO 6479864 <GO>}

Thank you very much and good morning and good afternoon to everyone. I hope you're
all safe and well, no matter where you are. I'm here with John Dacey, our Group CFO and
together with Thierry Leger, our Group Chief Underwriting Officer; and Thomas Bohun,
our Head of Investor Relations to talk you through the half-year results.
I'll just say a few remarks from my side before going into the Q&A session, so that you
get a bit of my perspective on this first half-year. So I'd say that overall as you can imagine
we're quite happy or very happy about the results because we see a lot of hard work that
went into the businesses over the last two years. Finally paying off and being visible.

Page 1 of 17



Company N ame: Swiss Re AG
Company Ticker: SREN SW Equity
Date: 2021-07-30

FINAL

The results were -- the underlying results last year were already quite a bit better, but
overshadowed by COVID. Well this year I think it's in the open and extremely visible. If I
quickly go through the different businesses. I look at P&C Re with 94.4 combined ratio. I
think that's an excellent result. Also normalized 94.4, it's below the target we have set of
95% combined ratio.
On top I remember the skepticism in this circle in January when we took some quite
radical actions on the underwriting side to cut some of the casualty business and some of
the aggregates and nat cat. I think you could see that we could catch up with the volume
by year-to-date where 85% of the renewals is now done and we are flat, but was a
significantly better portfolio and further price increases.
Despite the fact that with our scale, the efficiency, and the Life & Health Re diversification
with a combined ratio of 94.4. We have a very high ROE already. So I'm very pleased with
P&C Re and the trajectory it is in. Life & Health Re obviously heavily impacted by COVID. I
think everybody has been surprised by the huge amount of deaths unfortunately in the
US, but also in India, South Africa. So we pay for that with all the underwriting measures
we took on the wording side that the 01/01 renewal actually are in full effect and you can
see that very little losses are left in CorSo and P&C Re.

Bloomberg Transcript

The underlying in Life & Health is also looking very good. I'd just be a little bit cautious
here because this is on the exact science how to separate COVID from non-COVID
losses as you know this different methodologies you can try to estimate that. And so a bit
cautious around the underlying here, but overall Life & Health Re, the technical side has
worked very well also in this first half year.
And then CorSo, I'm very pleased in my eyes the turnaround is finished successfully
completed and you can see the results here now. They continue to have price increases.
They had year-to-date 13%, which is quite something, I would say, and that's as you know
will be earned over about two years. So the momentum is very strong, continues to be
strong. You've noticed that the normalized one is still above -- the normalized combined
ratio is still above the target we have, but causes in the trajectory. So we're very confident
to be able to hit that when you look at the full year figures.
And so, yeah, very pleased with the overall direction where they stand and the position
they have in the markets. And then finally on the COVID losses. We continued I think to
have a good estimate. We are very comfortable about the overall estimate. There's still a
big portion of IBNRs as you have seen in the slides I think it's 43%.
So time will tell how much we need that, but at this stage, we feel that's the best guess
we can have at the final losses. And, as I said before, it's tapering off on the CorSo and
P&C side. We gave a figure of less than 200 million on these two business lines until the
rest of the year.
And then on the Life & Healthy side, it will obviously very much depend on how many
deaths we have in the markets we are active in. I think there's encouraging signs looking

Page 2 of 17



Company N ame: Swiss Re AG
Company Ticker: SREN SW Equity
Date: 2021-07-30

at the UK, in particular, with the delta variant and number of cases are now going down
and for all these fourth wave a very, very significant reduction in hospitalization and tests.

FINAL

So vaccines are working against all variants at this stage. And if that's the case then I think
that bodes well for the rest of the year and beyond. So that's just a few remarks. I'm sure
you have more questions. And therefore, I'd like to hand over to Thomas Bohun who will
lead into this Q&A.

Thomas Bohun

{BIO 22165501 <GO>}

Thank you very much, Christian, and hello to all of you from my side as well. So before we
start, as usual, if you could restrict yourself to two questions and then rejoin the queue if
you have additional questions.
With that, operator, could we have the first question please.

Questions And Answers
Operator
The first question comes from the line of Andrew Ritchie with Autonomous. Please go
ahead.

Bloomberg Transcript

Q - Andrew Ritchie

{BIO 18731996 <GO>}

Hi, there. Good afternoon. I guess I'm normally the first to ask. Two questions. Both
relating to comments that John made this morning. First of all, you used the term
protecting the yield of the fixed income portfolio. Hence there was much lower fixed
income realized gains. I mean over the last five years, 70% of Swiss Re's realized gains
have come from fixed income. So I'm not quite sure how to take that sort of the guidance
I suppose. You're expecting non-fixed income returns, I guess returns on alternatives in
particular to make up for the loss of fixed income realized gains or maybe you could just
guide us to where we should think the running yield on your new definition should go to. I
noticed the underlying fixed income recurring income has dropped quite materially vary
materially year-on-year. So just -- I'm just trying to interpret what you're saying about this
protecting yield. It seems like it's a new element. The second question is, again, John you
made a comment, it's on Bloomberg, it's -- it's a headline I can't see the detail, you say
that insurers need to be quote more realistic on weather losses. Who are you referring to
there, your seasons people buying reinsurance or the industry in general. And I guess in
that context, does that signal that you need to think again about where you're positioning
in terms of nat cat versus frequency or who you're aiming that comment at? Thanks.

A - John Dacey

{BIO 4437051 <GO>}

I guess I'll answer these two questions, Andrew. Thanks for asking them. With the first one
on the -- you're right I was quoting protecting the yield. I think in the first half of the year
we just wanted to the point out that the relatively solid investment results 3.2. We got
delivered without having to move on the fixed-income portfolios in a point where the
Page 3 of 17



Bloomberg Transcript

FINAL

Company N ame: Swiss Re AG
Company Ticker: SREN SW Equity
Date: 2021-07-30

outlook on future interest rates is unclear. And so I think we're comfortable at the moment
or we're comfortable during the first half of the year that -- one the continued caution
around credit. We've managed to avoid any impairments whatsoever on the credit side
and the positive marks we got on the private equity portfolio in particular were more than
sufficient for us to go through the quarter. I don't think you should interpret this as a -- us
giving up intelligent moves in the fixed income portfolio when we see opportunities to
realize a reasonable level of gains, but we're not going to squeeze the portfolio down to
nothing when reinvestment rates are where they are. As you said the recurring investment
yield is down to 2.3% from 2.5% a year ago. That's not surprising given where interest
rates are the tenure was climbing back up 1.7, but the one last I checked this morning I
think we're back. It's 125 [ph]. So we're just going to have to manage through this. The
most important thing is that we're pricing our business to reflect the current yield
environment and not some hopeful reversion scenario. And that's what's going on. So I
think we're fine. I don't think you should interpret this is a -- any material change in
strategy. Just a recognition that during the first half of the year, we were able to move
forward and achieve this without any significant realization of gains out of credit and/or
other fixed income instruments. On the second one. The Bloomberg quote -- to the
degree that I was aiming at any one. I think it is both for the primary industry and frankly
people that buy retail insurance. The reality is the -- what we've priced into our rates for
secondary perils is what we think needs to flow down into homeowners in Florida or in
California to commercial enterprises around the world to be able to deal with the losses
that we see from more extreme weather events. It doesn't mean that we need to do
another round of improvements in our models. Our models we think are already reflecting
the current reality, but not everyone agrees with us on where some of these prices have
been. We've -- the classic example was in the State of Florida where we've continued to
be underweight because we think the prices that start at the very beginning of this chain
are not reflecting the risks that are there. And so over time, we hope to be able to
demonstrate that our picks, which seem to be relatively high are the right picks for people
to go with. And if that cascades down into underlying policies, that's the right answer. A
great example of where that did happen for us was frankly in Japan property after the
typhoons of 2018 and 2019 where the primary companies fundamentally change their
rates as a result of the pressure that we put on them in our reinsurance side.

A - Thomas Bohun

{BIO 22165501 <GO>}

Thank you, Andrew. Could we have the next question please?

Operator
The next question comes from the line of Will Hardcastle with UBS. Please go ahead.

Q - Will Hardcastle

{BIO 16346311 <GO>}

Hey, there. Good afternoon, everybody. Two questions. The first one is, I guess, a
compare to this week suggested it would be looking to increase its catastrophe budget
expectations in light of recent track record. I guess, in that regard, are you still confident
that your catastrophe budget is struck sufficiently robustly. So could this be something that
Swiss Re's looks at as well. And then the second one is within prior year development. It's
a very small number, it's nice to see that the adverse development on casualty lines and it
has come down a long way. Is it possible to break this out perhaps in quantum between
Page 4 of 17



Company N ame: Swiss Re AG
Company Ticker: SREN SW Equity
Date: 2021-07-30

the adverse development on North America liability and cyber versus at favorable
workers' compensation development and what drove the adverse. Is it just specific cases
or are there any assumption changes within that? Thanks.

A - Thomas Bohun

{BIO 22165501 <GO>}

Bloomberg Transcript

FINAL

John, would you like to take those questions?

A - John Dacey

{BIO 4437051 <GO>}

Sorry, the microphone. Well, the first one, our belief is that we've got and we frankly look
at every year and during the course of the year. The expected losses we've got on nat
cat. We allocate that during the course of the year with a overweight in Q3. So we've got
a larger expected budget on Q3 than any other quarter and it served us well. And frankly
with the exception of 2017 in the HIM losses. I don't know that we've been particularly far
off over any longer period of time. We've actually been very, very close to budget on
average. No, any particular year is going to be up or down given the good or bad luck. So I
think you should expect that we do review this constantly and we're comfortable where
we've got the picks for this year and that has on nat cat alone probably 700 million
expected losses between reinsurance and CorSo for the third quarter and that doesn't
include the large man-made events. On the prior-year development, you're asking for a
level of specificity, which I don't think we're going to provide. What I can say is in any one
quarter, we evaluate different lines of business and if there are places where we think we
-- it would be prudent to reinforce certain reserves, we'll do that. But on a net basis, the
reality for P&C Re has been very clear. It's been positive for the year-to-date. We don't
believe we've got any holes in the reserving positions. We'll continue to evaluate if we've
got new information or new events that make us think that we should do that. We'll
reinforce where we need to, but the good news is, we found redundancies and many
other parts of the book, whether it's in the property side, some of the accident and health
businesses other places and we've been able to fully cover the funding of some minor
adjustments during actually for the last four quarters now.

A - Thomas Bohun

{BIO 22165501 <GO>}

Thank you, Will. Could we have the next question please?

Operator
The next question comes from the line of Kamran Hossain with RBC. Please go ahead.

Q - Kamran Hossain

{BIO 17666412 <GO>}

Hi. Good afternoon. The first question is just following on from Will's one about cat
budget. Could you just talk a bit about how you actually calculate the cat budget. I guess
based on my understanding and conversations with other kind of companies and people
in the sector, a lot of cat budget you calculated on the backward-looking basis. So it's on
historical data kind of overlayed onto your portfolio. And the issue that these models have
is that they don't tend to factor in the change in climate. So just a few words on kind of
how you calculate the cat budget and kind of factor climate change, it seems like it is
happening into models. And the second question is just on the, I guess, the level of
Page 5 of 17



Company N ame: Swiss Re AG
Company Ticker: SREN SW Equity
Date: 2021-07-30

FINAL

prudent in your COVID reserves. Obviously the kind of 43% IBNR reflects kind of event
cancellation and mortality offers, but if I look at the kind of business interruption book, it
looks like you've got $1 billion plus of IBNR prevents that really happen more than a year
ago. So just interested in how those reserves that moved year-on-year whether actually
you would expect to get more clarity whether it would be claims will develop or not in the
coming quarters? Thanks.

A - Thomas Bohun

{BIO 22165501 <GO>}

Thierry, do you want to take the first question and then John, the second?

A - Thierry Leger

{BIO 16674977 <GO>}

Happy to. So on the nat cat budget. So the starting point is always with the expected loss.
So you have to imagine that in our costing we priced in an expected loss for a given year
for the business we write. So that's the starting position for defining the budget. And then
we do several adjustments with regard to profit-sharing agreements, reinsurance
premium, of course retro comes into play as well because the expected losses on
growth, late reportings and things like that, and that's how we get to the budget that we
disclose. And more specifically to your question around climate change. Of course, that is
part of our expected loss we start with. So as we actually change our views on our loss
pick, we for example, for climate change that would impact expected loss and accordingly
also the budget over time.

Bloomberg Transcript

A - Christian Mumenthaler

{BIO 6479864 <GO>}

Maybe if I could jump in, Thierry, because it could be that some reinsurers are really using
just historical loss data over the last 10, 20 years. And I think it's important to stress that
we have a team of dozens of nat cat experts who the program forward-looking model,
physical models for hurricanes for example et cetera. And of course their ambition is to
capture all trends and have a forward-looking view and model and that's the figure we
use here. So of course that gets calibrated indirectly when you do models, you always
calibrate to the back, but it includes all information we have about climate change for
example. So there should be definitely a forward-looking element in the cat budget you
can see.

A - John Dacey

{BIO 4437051 <GO>}

And Kamran, on your second question, with respect to the COVID reserves. You correctly
identified that the level of IBNR for the business interruption claims are around the
property book remains strongly in IBNRs. And this frankly reflects a current market
dynamic where the presentation of claims has been very slow from the primary markets.
And here we're -- in some cases they themselves are trying to come to a final conclusion
of what their losses are. And then thinking through the specific issues of event definition
and accumulation where, in some cases I'm guessing we'll have a pretty coherent view
ourselves of the way they are thinking about it. In other cases, we may have a seriously
different view of the way that they're looking to pull together a potential claim recovery.
So what I can say is there's been relatively little movement on this specific bucket in the
property side over the last two quarters. I would expect probably around year-end as we
look again to the renewal season that we might sort out some of the uncertainty, but this

Page 6 of 17



Company N ame: Swiss Re AG
Company Ticker: SREN SW Equity
Date: 2021-07-30

FINAL

is probably going to continue into next year at some level. So I wish we were in a different
state, as an industry we're not -- and there's not much we can do until the primary
markets come to us with a clear proposal about what they're expecting and we can either
agree or disagree with that. So the discussions have been occurring. I don't want to say
that there has been no discussions or nobody thinking about this, but it remains as you
say a big chunk of this 1.4 billion that we've got in this bucket to be resolved. We continue
to believe that we are well reserved.

A - Thomas Bohun

{BIO 22165501 <GO>}

Thank you, Kamran. Could we have the next question please?

Operator
The next question comes from the line of James Shuck with Citi. Please go ahead.

Bloomberg Transcript

Q - James Shuck

{BIO 3680082 <GO>}

Hi. Thanks very much. Good morning and good afternoon. So my two questions. Firstly, on
the fixed income running yield in the I think certainly in the appendix. I mean if I think the
886 for the first half of the year. It's look like a yield of about 3.1% and I think you're saying
that new money at the moment is about 1.25 at least based on the treasuries. Can you
just remind me about your strategic asset allocation and where you are versus that and
how we should think about the scope to re-risking. I think your market risk is shown in the
SCR is actually quite low by historical standards. So if I just annualize that fixed income
yield sort of around 1,800, 1,900 or so. Is that number directionally going to go up as you
change the asset allocation. That's my first question. Secondly on CorSo, I hear the
comments that you say Christian about very confident with the outlook in the trajectory.
Just a bit puzzled about the first half result because it's 97.7 normalized, but that's not
normalized for man-made losses and man-made losses were about two point benefit. So
excluding that sort of closer to 99 or closer to 100. So when you make your comments
around contract to below 97 that's getting the benefit from a low level of man-made
losses. So just comment about why is you're so confident you're on track versus plan
would be helpful? Thank you.

A - Thomas Bohun

{BIO 22165501 <GO>}

John, do you want to take the first question and then Christian, the second?

A - John Dacey

{BIO 4437051 <GO>}

Yeah, sure. So, James, with respect to the current investment portfolio. I think on the slide
deck in the appendix we had on page 25 or 26. Looks like I have trouble reading this with
this slide, 26. 40% government bonds, 30% in credit, another 10% in equities and
mortgages and other loans, some policy loans. So I think that, to give you a sense, we
have increased modestly the risk from the beginning of the year. We've reduced our cash
position from 17% down to 14%. We continued to have some runway if we want to bring in
additional risk onto the balance sheet at this point of time. I think we, as a management
team, is reasonably comfortable with where they are. So the underlying point you have
which says will this -- with current interest rates, will this return and the recurring
Page 7 of 17



FINAL

Company N ame: Swiss Re AG
Company Ticker: SREN SW Equity
Date: 2021-07-30

investment yield continue to trend down. The answer is probably yes. I don't think
anything dramatically, but -- we don't see an inflection point on this. We'll look to continue
to see what's available on the alternative side and we've got teams that have done a very
nice job frankly in private equity and other alternatives to support a strong yield, but the
core fixed income side of this is not just for Swiss Re, but for the industry going to be
under some modest pressure with reinvestments. And that's why the kind of price
increases we've seen corporate solutions we need to continue the underlying primary -industry getting those rate increases helps us directly on that side, but also frankly as a
spillover effect to our reinsurance portfolio as well.

A - Christian Mumenthaler

{BIO 6479864 <GO>}

Yeah, and of course I think you're right. If you add man-made we come to a slightly lower
number. So our team would say 98 point something. But if you look at the trajectory of the
price increases and that as it gets earned through over two years. I think mathematically, I
have quite some confidence that we get there by the end of the year. Just looking at the
pro with you quarter by quarter and how it gets earn through. But yeah, clearly we pushed
them down, we give them tough targets. They now have also elipsLife, which is a different
type of business and so on, but I am confident we will get to 97 at this stage.

A - Thomas Bohun

{BIO 22165501 <GO>}

Thank you, James. Could we have the next question please?

Bloomberg Transcript

Operator
The next question comes from the line of Iain Pearce with Credit Suisse. Please go ahead.

Q - Iain Pearce

{BIO 19522835 <GO>}

Hi. Thanks for taking my questions. The first one was on the dividend upstreaming from
the different segments. I know P&C Re didn't upstream any cash to group this half year
there any cash remittances from Life & Health. Is there anything to sort of flag there? Is it
due to the cash inflows you've had from some of the divestments or the sort of
restructuring that happened to the different operating entities and/or should we be
expecting a sort of normal remittance pattern in the second half of the year. And then just
following up on the corporate solutions point. Yeah, I was a bit surprised to see the
underlying development worsened this year on the combined ratio. So just if there's
anything to flag there as to why that has worsened. And if you look at slide four does the
historics include elipsLife and we're looking at underlying combined ratio?

A - Thomas Bohun

{BIO 22165501 <GO>}

John, do you want to take the first question?

A - John Dacey

{BIO 4437051 <GO>}

Yeah. So with respect to dividends. I mean you're right and the flag that we have done this
restructuring of the legal entities in Switzerland effective the 1st of July. I don't think I
would read anything into the -- what you saw in the first half. We continue to be highly
Page 8 of 17



Company N ame: Swiss Re AG
Company Ticker: SREN SW Equity
Date: 2021-07-30

FINAL

liquid both at overall the group, but also -- and more broadly in the consolidated
businesses. We'll think through what dividends we might want to see either in the second
half of this year or next year between the legal entities. But I don't think that there's any
particular cause for concern about our ability to manage both liquidity and capital between
the subsidiary and the parent company.

A - Thierry Leger

{BIO 16674977 <GO>}

Yeah, maybe the question on the normalized combined ratio. I think the issue here is, we
don't normalize for man-made to make it comparable to P&C Reinsurance. So if you did
the normalized with man-made last year would be higher, the combined ratio than it is
now. So I don't know -- I can't remember the exact figure but Investor Relations can
provide that to you.

A - Thomas Bohun

{BIO 22165501 <GO>}

Thank you, Ian. Could we have the next question please?

Operator
The next question comes from the line of Vinit Malhotra with Mediobanca. Please go
ahead.

Bloomberg Transcript

Q - Vinit Malhotra

{BIO 16184491 <GO>}

Yes, good afternoon. Thank you. So my first question is on the kind of the flood and the
weather we talked about and earlier in the year, we've been talking about the reduction in
the secondary perils. Are you able to give us some kind of direction or indication or some
kind of quantification that okay because affordable underwriting measures they were
slightly lower lots to be expected from this flood. So anything to that effect would be very
helpful. That's the first question. Second question is, John, there's a very strange remark
in Bloomberg headlines again might not be fully accurate, but just to see what I just read
out what I see. It says that you said there's still some more mortality. So continued to see
major mortality losses. And just to understand, I mean I would have assumed that from
your comments as well that mortality should trend down lot like from in second half, but if
you could just reiterate that or clarify that will be very helpful? Thank you.

A - Thomas Bohun

{BIO 22165501 <GO>}

Thierry, if you could take the first question and then John, the second?

A - Thierry Leger

{BIO 16674977 <GO>}

Yeah, I'll take the first one on the flood and the weather as you called it. So indeed, we
reduce our exposure to these secondary perils. And we were actually assuming at the
time, you will remember, we also talked about it already at the Investor Day. We were
assuming that the trend of the secondary perils, the volatility that we have seen emerged
over the last years is not going to go away suddenly. So we view this as a real trend. So
what we did do actually two things. One is one that John mentioned already was the
adjustment of models. For example, in Japan, that we have also adjusted the models in
Page 9 of 17



Bloomberg Transcript

FINAL

Company N ame: Swiss Re AG
Company Ticker: SREN SW Equity
Date: 2021-07-30

other areas and obviously we continue as we learn from new claims. We continue to
adjust our model. So that's the one thing we did, which leads over time to an increasing
loss pick. The other thing we did is, we looked at structures that we don't like and in this
regard we very closely looked at these cat aggregates that can actually pickup these
secondary perils quite easily and in a way, we didn't like as much anymore. So we did
indeed address those and reduce our exposure, but not only to these aggregate covers,
we also have the top and drop structure. So everything in that frequency area we did
reduce. And our own estimation is that it would certainly be a triple-digit amount of losses
and it was certainly a triple-digit amount of loss that we have avoided with those actions.

A - John Dacey

{BIO 4437051 <GO>}

And Vinit thanks for bringing up. I'm not quite sure exactly where the headline came from.
What I did say is the mortality losses, we're the only significant COVID loss that we had in
the first half of the year. And I'm not sure if that's was somehow misunderstood of my
point. What I can say very clearly is obviously, our biggest exposure for Life & Health
losses in COVID, our mortality losses and in the United States. We've had some losses in
other countries, in the past, the UK, not much on Continental Europe, but the US has been
dominant. What we saw was on Q1, our biggest single quarter because of the number of
deaths in January and February in particular that has tailed down considerably the Life &
Health losses overall reduced by 60% quarter two over quarter one. And given the trends
of vaccination and the continued success of the vaccines against the variants to-date, we
would, all things being equal, we expect that to continue to trend down. What we did see
in the second quarter was some losses that were booked from geographies, other than
the US, about half of that number that we've booked the 240 was US related. The other
half came from some other countries where losses were established reported India,
South Africa and some small numbers out of certain Latin American countries. We do not
expect that those numbers will be substantial going forward. What was booked in the
second quarter was loss is actually in the second quarter and probably a little bit of catchup from previous quarter deaths that were reported to us after considerable interactions
with the primary companies. So I think we would expect the run rate with what we know
today and the current trends of both the functionality efficacy of the vaccines vis-a-vis the
different variants and the slowing, but still increasing levels of vaccination to reduce these
losses in future quarters. I hope that helps.

A - Thomas Bohun

{BIO 22165501 <GO>}

Thank you, Vinit. Could we have the next question please?

Operator
The next question comes from the line of Thomas Fossard with HSBC. Please go ahead.

Q - Thomas Fossard

{BIO 1941215 <GO>}

Oh, yes, good afternoon. Two questions on my side. The first one would be related to
CorSo. I think that you're flagging the -- the end of the turnaround program at CorSo and
potential you're flagging more or return to more normal growth. So could you help us to
understand what we should expect now in terms of topline growth for CorSo
opportunities you're seeing, you're currently contemplating in the market. And if on top of
Page 10 of 17



Company N ame: Swiss Re AG
Company Ticker: SREN SW Equity
Date: 2021-07-30

FINAL

what you're getting in terms of rate increases we should stop thinking about growing
exposures. And then the second question would be related to the renewals. So year-todate, you're coming with 4% nominal price change. Can you update us on what the impact
of those on the combined ratio basis, on a net profit basis and at the end of the day I'm
guessing that it's net of everything, it's 2% higher. So just was wondering if you could put
some qualitative comment on this and say in your view this is enough or I mean actually it
needs to be further improved going forward? Thank you.

A - Thomas Bohun

John, would you like to take the first question?

A - John Dacey

Bloomberg Transcript

{BIO 22165501 <GO>}

{BIO 4437051 <GO>}

Yeah, so with respect to the CorSo, I think it's important to remember that Andreas
Berger came in 2019 and took responsibility, the pruning was severe, a third of the
portfolio was jettison. Teams were shutdown, disbanded and picked up in some cases by
some competitors, but we were consequent in removing ourselves from certain lines of
business, whether it's excess and surplus liability in the US umbrella liabilities. We just
decided that we would be better off not in these lines of business. And for the absence
of doubt, there is no reconsideration of those lines that we did exit from. We're very
comfortable that we can move forward without necessarily being players and what we
consider to be more challenging lines at least over any reasonable period of time. What
we have reached is the inflection point and that's what you see actually here in the first
half where premiums are starting to grow again not by much, but as a result of these
price increases coming through on the book of business and the potential expansion in
certain lines. So the European property book of CorSo is growing. We're adding new risks,
but we're also getting good pricing. We would expect then to see an increase in
premiums earned at the very least from these price increases. They may not be 13% in
the next quarter. We're not making a prediction of what they are, but there is momentum
carrying the commercial rates forward. So even if the book doesn't necessarily grow very
much this momentum on earned we should see. And to the degree that the CorSo does
see valuable opportunities for writing new business in lines where they're already present.
They've got our support and we've encouraged them to put that capital to work. So there
is -- we're not making a prediction on where they're going to end the year, but I'd be very
surprised if you wouldn't see some acceleration of the growth from where we are today.

A - Thomas Bohun

{BIO 22165501 <GO>}

Thierry, on renewals.

A - Thierry Leger

{BIO 16674977 <GO>}

I'll start on the renewal and quality question, Thomas, that you have. So indeed you are
right there's this nominal price increase that we disclose and against that we have the
yield increase that we observed earlier in the year and we have the loss pick that we
mentioned already that you have to set against it. And of course if you deduct them from
the nominal price increase and what's left is not as much as we promised the result
improvement will be. So the difference is actually and the difference is significant is
coming from the improved portfolio mix. So we've said that -- and if we have disclosed

Page 11 of 17



FINAL

Company N ame: Swiss Re AG
Company Ticker: SREN SW Equity
Date: 2021-07-30

that as well. So we are on the one side addressing our underperforming treaties in the
casualty space and in the property space. So one reduce exposure to social inflation LCR.
Those are typically treaties with the high combined ratio. And you are addressing the
lower layers on in for example cat and property and those are equally businesses we
have typically higher combined ratio. So as we move more and grow more and by that I
mean also exposure into businesses with lower relatively lower combined and actually
reduce business with relatively high combined ratios. So overall we quite strongly improve
as a result, the combined ratio of the portfolio through an improved mix.

A - Thomas Bohun

{BIO 22165501 <GO>}

Thank you, Thomas. Could we have the next question please?

Operator
(Operator Instructions) The next question comes from the line of Ashik Musaddi with
JPMorgan. Please go ahead.

Bloomberg Transcript

Q - Ashik Musaddi

{BIO 15847584 <GO>}

Yeah, thank you, and good afternoon. Just a couple of questions I have, if I may. So first to
all. You mentioned that the expected losses on the recent floods et cetera is about mid
triple-digit million and then if I heard it correctly you mentioned that the third quarter
budget for cat losses is 700. So I mean that leaves a gap of this 200 million. How
confident you are that the hurricane season would not more or less exceed those extra
200 million net. I mean we are still left with the whole hurricane season. That's one
question I would ask. The second thing is, if I think about the growth I mean at the
moment, we are trying to make sure that the portfolio is more profitable especially in the
P&C Re business. Pricing is the main focus whereas volumes is not, but what needs to
happen for the volume to start picking up as well. I mean when do you think that the
volume get start moving higher as well in the P&C Re. I mean CorSo it's pretty clear. I
mean pricing is driving volume total premium as well by in P&C Re the premiums are still
kind of flattish. And the third one is, you mentioned there is 200 million of remaining
losses from COVID in P&C and CorSo, but like this quarter you have booked almost
nothing. So what is the reason for that 200 million. It's just because there's just no visibility
and uncertainty or is it that you have some line of sight which makes you put that 200
million? Thank you.

A - Thomas Bohun

{BIO 22165501 <GO>}

John, do you want to start on those?

A - John Dacey

{BIO 4437051 <GO>}

Yeah. So maybe I can. With respect to the floods. What we said is the combination of what
is a man-made event the social unrest in South Africa and the floods in Germany are likely
to be a mid three-digit loss. We will clearly be working on this in the next weeks to try to
get more precision on this. And as long as it's consistent with what these preliminary
estimates are, we'll just move forward, but I think with respect to the nat cat budget, you
should not expect that all of this is going to land in the nat cat, but the part in South Africa
Page 12 of 17



Bloomberg Transcript

FINAL

Company N ame: Swiss Re AG
Company Ticker: SREN SW Equity
Date: 2021-07-30

will be outside of that calculation for us. So I think we've probably got a little more room
than you might indicate if we -- our preliminary guesses are there. We do have some
expectations for man-made losses, which would take the number over 800 million when
you combine it with the nat cat budget. The third question, I think I'll answer as well. With
respect to future P&C losses on COVID. What we said at the beginning of the year is, we
still saw three potential opportunities for us to take losses. One is the very constrained
exposure we now have on property treaties that are multi-years or otherwise might pick
up some losses if there were to be a new set of lockdowns, obviously, that's not
happened in any material way into the first half of the year. The second was on the event
cancellation. What I can say there is one good news, lots of events are occurring including
the Tokyo Olympics. Very pleased to see, but also even some of the other ones that
were canceled. What we saw was the ultimate cost of that cancellation was lower than we
might have had reserved especially in the CorSo book. And so what you saw in the
second quarter was actually a bit of a positive on event cancellation, which covered some
modest losses of the places. And the last on the credit and surety side, the reality is the
governmental support in fiscal stimulation continues to keep companies in pretty good
shape. And so we didn't see anything, any material losses that we would have linked to
COVID activity in the first half of the year on credit and surety are very small. The 200
million that we take for what's left in the year is basically a maximum amount if things
were to go relatively poorly in those categories for the second half of the year. If they go
well, it will be a lot less than $200 million, but we're not prepared to predict that at this
point of time, but I think we specifically use the phrase less than $200 million to give you a
maximum that we would expect and it may well be materially less than $200 million given
the experience we've had in the first half of this year. There's nothing we see on the
horizon, which says, we're going to be close to that number to date.

A - Thomas Bohun

{BIO 22165501 <GO>}

Thierry, on the growth opportunities?

A - Thierry Leger

{BIO 16674977 <GO>}

Yeah, on the volume pickup. So I mentioned I think and John mentioned to say there are
underlying lines of business that we are growing that CorSo has been growing that P&C
Re has been growing through the whole transformation and turnaround they have been
through. So nat cat has been an area where we have always found spots of nice growth
and that's also what we have seen in the first half this year. I mentioned specialty across
CorSo and P&C Re. We have seen very attractive growth there lies for example in credit
and surety where we are still a bit down on the brakes currently, but that could potentially
if the markets become attractive become another area of growth for us. Casualty has
been much more careful because social inflation is here to stay very clearly and there are
no signs or indications that this would go away. To the contrary, we think this social inflation
impact could also move into other lines and therefore certain on casualty, we will remain
careful. The other elements that is difficult to predict how it's going to evolve is that we've
seen a trend generally to non-proportional which in my view is a very good trend. It's
usually a trend to quality portfolio when we move because we have very, very good
understanding of non-proportional costing. So that's usually a sign of confidence and very
positive, but we have seen a decline in the first half on the proportional business, and
that's very difficult to predict how will the commissions behave with our customers what
actions do our customer take on their portfolios, all of that is more difficult to predict. But
Page 13 of 17



Company N ame: Swiss Re AG
Company Ticker: SREN SW Equity
Date: 2021-07-30

equally there, if opportunities present themselves, we will try and find opportunities to
grow there too.

A - Thomas Bohun

{BIO 22165501 <GO>}

FINAL

Thank you, Ashik. Could we have the next question please?

Operator
The next question comes from the line of Vikram Gandhi with Societe Generale. Please go
ahead.

Q - Vikram Gandhi

{BIO 18019785 <GO>}

Hello. Good afternoon. It's Vikram from SocGen. Hope all of you are doing well. I've just
got one question. We've seen some settlements in the US with regards to the opioid
crisis. I know the group has been fairly cautious on the casualty side over the past year,
year and a half, but if you can just share some of your thoughts as to your level of comfort
with the historical pharma sector exposure, that would be great? Thank you.

Bloomberg Transcript

A - Thierry Leger

{BIO 16674977 <GO>}

Yeah, Vikram, thanks for this. So we have had historically I mean we were among the first
move is early 2000 with regard to pharma exposures with pharma exclusion that we have
implemented in across our businesses since. So I think I can say with confidence that we
have been adopting a very cautious approach to pharma exposures in particular. So
however, we do find still exposures, but certainly it's a very measured approach we take
still today and the settlements that we -- you see you read in the news all of those were
ongoing settlements we've been observing monitoring, but none of them has been a
surprise to us and is in line with our expectations I would say. So no particular bad news or
good news to us.

A - Thomas Bohun

{BIO 22165501 <GO>}

Thank you, Vikram. Could we have the next question please?

Operator
The next question is a follow-up from Mr. Thomas Fossard with HSBC. Please go ahead sir.

Q - Thomas Fossard

{BIO 1941215 <GO>}

Yes, thank you. Just wondering if you wanted to make any comments on your capital
position at midyear direction and actually you disposed also couple of stakes since the
start of the year. So any hints on what could be the use of them and if you've got some
idea and care plans already? Thank you.

A - John Dacey

{BIO 4437051 <GO>}

Page 14 of 17



FINAL

Company N ame: Swiss Re AG
Company Ticker: SREN SW Equity
Date: 2021-07-30

Thomas. Hi, it's John. Look what we've indicated is that our SST ratio is above the
midpoint. As of June 30th, we'll go through the work we have to go through to get a
more precise answer and share that with the markets with the third quarter results. So the
robustness of a capital, I don't think anybody questions. Your question I think is going
further than that which is, are there going to be any additional capital measures. I think it's
premature to discuss those. We'll obviously look to complete the year. We are very much
pleased with the first half performance and with the underlying economic earnings as well
as the US GAAP earnings that are coming through. And so we'll see how this plays itself
out in the second half of the year, but our overall capital framework remains intact. We
look to make sure that we've got a very strong position. Check that box too. We support
important growth that's what you see doing. The premiums were up. Earned 8%. Life &
Health Re I think is a franchise that you should not ignore in terms of the relatively strong
growth that we continue to see there in terms of value creation. And frankly even if it
remains a very small business or etiquette business is another place where we're
continuing to invest in as it grows very, very strongly year-on-year. If we find ourselves in a
great position with more capital than we know what to do with and we'll come back to you
with some of those ideas.

A - Thomas Bohun

{BIO 22165501 <GO>}

Thank you, Thomas. Could we have the next question please?

Operator

Bloomberg Transcript

The next question comes from the line of Ivan Bokhmat with Barclays. Please go ahead.

Q - Ivan Bokhmat

{BIO 15378004 <GO>}

Hi, good afternoon. Thank you. I've got a couple of questions. The first one is on Life &
Health Re. Just wondering the underlying performance excluding COVID has obviously
been very strong for a couple of quarters running now. I was just wondering if you could
share some views on the drivers, some of the stuff we're reading is that the flu pandemic
has actually been very benign. So just wondering if there is any one-off effects that you
can flag within those numbers. And secondly just on some of the earlier comments you've
made on the increasing the nat cat exposure. Obviously you said that you're still being
very selective on the regions and then the types of coverage you take, but I was
wondering if you could just suggest which geographic areas have you been growing into if
it's let's say not Florida and how is the portfolio changing? Thank you.

A - Thierry Leger

{BIO 16674977 <GO>}

Okay. So on the Life & Health underlying drivers. We Christian mentioned I think it's an
important point that the allocation between the COVID losses and non-COVID losses is
somewhat sometimes a bit of an intellectual debate and not an straightforward. So there
could be some element or noise coming from that allocation. We have seen, however,
positive mortality developments for example across the board. And we've seen good
developments in disability for example in Australia, which was positive after some more
difficult quarters and we have also seen some positive developments in China. So
generally a positive underlying technical result. But we say that we shouldn't take this
obviously as an indicator for the second half of the year. On the nat cat side we go -- you
Page 15 of 17



Company N ame: Swiss Re AG
Company Ticker: SREN SW Equity
Date: 2021-07-30

FINAL

used the word selectively. I think selectively has more to do with structures and with
specifically frequency related layers, but otherwise we model 185 different perils and
we're actually very, very keen to grow every single one of those. So there is no particular
preference on areas where we are indeed very cautious. So we have been historically
cautious. Historically is a big word but cautious over the last year in Florida, for example,
but that is no news. And other than that, as I just said, we have actually quite balanced
appetite across the board and then, yeah, I think there is not much more I can say.

A - John Dacey

{BIO 4437051 <GO>}

Maybe if I could just add on the first point on the Life & Health underlying performance. As
Thierry said, the technical performance has been strong universally across geographies
and products. We're pleased with that. It's a little unusual. Normally there's one or two
places where you might see some a temporary relapse to a less good situation. The
other thing, the current return on equity has been flattered by a relatively low level
compared to where we set the targets at 10% to 12%. The business was supported by a
notional $8 billion of equity capital. The reduction of the unrealized gains in supporting
that business has reduced that below 6 billion I think right now and we've got a situation
where the ROE looks good in part because the ease more constrained. But the earnings
themselves at over 500 million for the first half of the year or probably better than
anticipated and no matter how you own it at the high end of the -- of what we might have
expected.

A - Thomas Bohun

{BIO 22165501 <GO>}

Bloomberg Transcript

Thank you, Ivan. We probably have time for one more, if there's someone waiting in the
queue.

Operator
Yes, we have a follow-up question from Mr. Andrew Ritchie with Autonomous. Please go
ahead.

Q - Andrew Ritchie

{BIO 18731996 <GO>}

Oh, hi, there. I think there are fairly short ones. Apologies if this is a simplistic question. I'm
curious as to why the loss cost assumption in the pricing disclosure. So it was you gave us
a nominal price in January and you knocked off 1.5 points, 1.5% for loss costs and that's
become minus 1. I guess I'm just setting in the context of generally there has been an
increase in loss cost expectation across the industry year-to-date given the inflationary
backdrop. How come that's not the case for you assuming that's something to do with the
mix of the type of renewal, but if you could just clarify that. And the second question I
think is also for Thierry. On the nat cat growth and thinking specifically US, obviously, we
are in hurricane season. When I think about your exposures, have they grown across all
return intervals or is it more 150 and return it below that. Is there anything unusual about
the growth across the return intervals?

A - Thierry Leger

{BIO 16674977 <GO>}

Page 16 of 17



FINAL

Company N ame: Swiss Re AG
Company Ticker: SREN SW Equity
Date: 2021-07-30

I put myself off. So on the loss cost assumptions that you've mentioned. Indeed, we have
reduced that slightly. When you look at the numbers we disclosed, in reality it indeed has
to do with the mix of business that obviously has an impact as well on this number. So we
have been growing more in specialty and property and the adjustment on the loss pick
side has just been much smaller compared to what we actually think we need on for
example casualty. So that explains that relatively in my view anyway small change between
earlier part of the year and the later part. The second point on nat cat US. So we have
indeed changed somewhat the exposure to the different you called it I think return
periods. So we have clearly moved the way from the higher return periods, but those are
the five, ten-year return periods. We are talking about and moved into what we call the
belly somewhere in the middle part. So not necessarily to the 150 years plus that you
mentioned.

A - John Dacey

{BIO 4437051 <GO>}

And, Andrew, I might just add on Thierry's first answer. Even on the January one renewals,
we took a position on coming inflation that related to not just social inflation, but also the
risk a broader-based inflation and that was in the pricing model. So I think while it became
a bit fashionable for people to talk about cost of goods and other loss inflation in the
middle of that half year. We've already made some moves earlier on for those inflation
assumption. So you might not have seen that delta increase in our own cost fee models
that you're thinking about.

Bloomberg Transcript

A - Thomas Bohun

{BIO 22165501 <GO>}

So with that we've come to the end of the call. I would like to thank you all for attending.
Thank you for your questions. If you have any additional questions, please reach out to the
Investor Relations team. Have a nice weekend, and thank you again. Operator, back to
you.

Operator
Thank you for your participation, ladies and gentlemen. you may now disconnect.

This transcript may not be 100 percent accurate and may contain misspellings and other
inaccuracies. This transcript is provided "as is", without express or implied warranties of
any kind. Bloomberg retains all rights to this transcript and provides it solely for your
personal, non-commercial use. Bloomberg, its suppliers and third-party agents shall
have no liability for errors in this transcript or for lost profits, losses, or direct, indirect,
incidental, consequential, special or punitive damages in connection with the
furnishing, performance or use of such transcript. Neither the information nor any
opinion expressed in this transcript constitutes a solicitation of the purchase or sale of
securities or commodities. Any opinion expressed in the transcript does not necessarily
reflect the views of Bloomberg LP.  COPYRIGHT 2022, BLOOMBERG LP. All rights
reserved. Any reproduction, redistribution or retransmission is expressly prohibited.

Page 17 of 17

